Background: Our understanding of the molecular pathways that underlie melanoma remains incomplete. Although several published microarray studies of clinical melanomas have provided valuable information, we found only limited concordance between these studies. Therefore, we took an in vitro functional genomics approach to understand melanoma molecular pathways. Methodology/Principal Findings: Affymetrix microarray data were generated from A375 melanoma cells treated in vitro with siRNAs against 45 transcription factors and signaling molecules. Analysis of this data using unsupervised hierarchical clustering and Bayesian gene networks identified proliferation-association RNA clusters, which were co-ordinately expressed across the A375 cells a...
Single-cell sequencing technology provides insights into the pathology of complex diseases like canc...
<p>(<b>A</b>) Heatmap of five patient-derived metastatic melanoma cell lines. Metastases of human me...
Development and validation of robust molecular biomarkers has so far been limited in melanoma resear...
BACKGROUND: Our understanding of the molecular pathways that underlie melanoma remains incomplete. A...
BACKGROUND: Our understanding of the molecular pathways that underlie melanoma remains incomplete. A...
Metastatic melanoma patients have a poor prognosis, mainly attributable to the underlying heterogene...
<div><p>Metastatic melanoma patients have a poor prognosis, mainly attributable to the underlying he...
Background: Current clinical and histopathological criteria used to define the prognosis of melanoma...
Because the prognosis of melanoma is challenging and inaccurate when using current clinical approach...
Despite new treatment options, prognosis of many melanoma patients remains poor and new treatment st...
Objective: Our aim was to explore the engendering mechanism and gene targets for melanoma. Methods: ...
Understanding the biological factors that are characteristic of metastasis in melanoma remains a key...
In melanoma, there is an urgent need to identify novel biomarkers with prognostic performance superi...
ABSTRACT: Objective: To identify novel biomarkers and therapeutic targets for primary melanoma usin...
Abstract Objective Melanoma accounts for 80% of skin cancer deaths. The pathogenesis of melanoma is ...
Single-cell sequencing technology provides insights into the pathology of complex diseases like canc...
<p>(<b>A</b>) Heatmap of five patient-derived metastatic melanoma cell lines. Metastases of human me...
Development and validation of robust molecular biomarkers has so far been limited in melanoma resear...
BACKGROUND: Our understanding of the molecular pathways that underlie melanoma remains incomplete. A...
BACKGROUND: Our understanding of the molecular pathways that underlie melanoma remains incomplete. A...
Metastatic melanoma patients have a poor prognosis, mainly attributable to the underlying heterogene...
<div><p>Metastatic melanoma patients have a poor prognosis, mainly attributable to the underlying he...
Background: Current clinical and histopathological criteria used to define the prognosis of melanoma...
Because the prognosis of melanoma is challenging and inaccurate when using current clinical approach...
Despite new treatment options, prognosis of many melanoma patients remains poor and new treatment st...
Objective: Our aim was to explore the engendering mechanism and gene targets for melanoma. Methods: ...
Understanding the biological factors that are characteristic of metastasis in melanoma remains a key...
In melanoma, there is an urgent need to identify novel biomarkers with prognostic performance superi...
ABSTRACT: Objective: To identify novel biomarkers and therapeutic targets for primary melanoma usin...
Abstract Objective Melanoma accounts for 80% of skin cancer deaths. The pathogenesis of melanoma is ...
Single-cell sequencing technology provides insights into the pathology of complex diseases like canc...
<p>(<b>A</b>) Heatmap of five patient-derived metastatic melanoma cell lines. Metastases of human me...
Development and validation of robust molecular biomarkers has so far been limited in melanoma resear...